--- title: "Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN" type: "News" locale: "en" url: "https://longbridge.com/en/news/295255362.md" description: "Kahn Swick & Foti, LLC is investigating the proposed sale of Supernus Pharmaceuticals to Indivior Pharmaceuticals. The firm is examining whether the exchange ratio of 1.5401 Indivior shares for each Supernus share adequately values the company and if the transaction process was fair. Shareholders concerned about potential undervaluation are encouraged to contact the law firm to discuss their legal rights." datetime: "2026-08-07T15:38:42.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295255362.md) - [en](https://longbridge.com/en/news/295255362.md) - [zh-HK](https://longbridge.com/zh-HK/news/295255362.md) generator: "portal-rs" --- # Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN **Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN** Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN) to Indivior Pharmaceuticals, Inc. (Nasdaq: INDV). Under the terms of the proposed transaction, shareholders of Supernus will receive 1.5401 common shares of Indivior for each share of Supernus that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at (833) 538-3612, or visit https://www.ksfcounsel.com/cases/nasdaqgm-supn/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com. CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn KSF Managing Partner Lewis S. Kahn lewis.kahn@ksfcounsel.com (833) 538-3612 Kahn Swick & Foti, LLC 1100 Poydras St., Suite 960 New Orleans, LA 70163 View source version on businesswire.com: https://www.businesswire.com/news/home/20260807988617/en/ ### Related Stocks - [SUPN.US](https://longbridge.com/en/quote/SUPN.US.md) - [INDV.US](https://longbridge.com/en/quote/INDV.US.md) ## Related News & Research - [SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders](https://longbridge.com/en/news/297401736.md) - [Great Lakes Advisors LLC Acquires Shares of 29,800 Supernus Pharmaceuticals, Inc. $SUPN](https://longbridge.com/en/news/296676820.md) - [Top Indivior Insider Quietly Ramps Up Stake in Bold New Move](https://longbridge.com/en/news/297262729.md) - [Sun Pharma signs US drug pricing deal, secures tariff relief for 2 years](https://longbridge.com/en/news/297591064.md) - [MrBeast, Snapchat, AI and more: Pharma marketing’s pulse check](https://longbridge.com/en/news/297343211.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**